52
OXURION ANNUAL REPORT 2021
of Harvard College, Oxford University and Harvard Business
School. Thomas replaced his father, Landon Clay, who led the
first external investment into Oxurion and resigned from the
Board of Directors in 2011.
Dr. David Guyer, M.D., Non-Executive, Independent Director
Dr. David Guyer, M.D., is a long-standing member of the US
retina community and is currently the Co-founder, President,
and CEO of EyeBio. David is also a Venture Partner at SV
Health Investors and is Co-Founder and former CEO and
Executive Chairman of IVERIC bio (formerly Ophthotech
Corporation). He was previously the CEO of Ophthotech. Dr.
Guyer is also on the board of directors of iStar Medical and
Eye-Point Pharmaceuticals. He co-founded and served as
CEO and a Director of Eyetech Pharmaceuticals, Inc., where
he led the company through private, public and corporate fi-
nancings, and oversaw the rapid development and successful
commercialization of Macugen® (pegaptanib sodium), the
first FDA-approved anti-VEGF pharmacological treatment for
the treatment of wet AMD. Dr. Guyer has also had a success-
ful career in academic medicine as Professor and Chairman
of the Department of Ophthalmology at New York University
School of Medicine. Dr. Guyer received his Bachelor of
Science (BSc) degree from Yale College summa cum laude
and his medical degree (MD) from Johns Hopkins Medical
School. He completed his ophthalmology residency at Wilmer
Ophthalmological Institute at Johns Hopkins Hospital and a
retinal fellowship at the Massachusetts Eye and Ear Infirmary
at Harvard Medical School.
Emmanuèle Attout (INVESTEA SRL), Non-Executive,
Independent Director
Emmanuèle Attout was an audit partner at
PriceWaterhouseCoopers from 1994 to 2014, in charge of
audits of a range of clients in various sectors, including listed
companies and pharmaceutical and life sciences companies,
from which she brings substantial relevant experience to the
Board of Directors and to the Audit Committee. Emmanuèle
is an independent Non-Executive Director, chair of the Audit
Committee, of Atenor SA, AG Insurance SA/NV and Schréder
SA. She is a supervisory board member of Eurocommercial
Properties NV. Since 2009, Emmanuèle is co-founder
and director of the NGO Women on Board. Emmanuèle
graduated in Applied Economic Sciences at the UC Louvain.
Baron Philippe Vlerick, Non-Executive, Independent
Director
Philippe Vlerick is the owner, Chairman and CEO of several
businesses in Belgium and abroad. He currently serves as
the Chairman and Chief Executive Officer of Vlerick Group
(Belgium), and as Chairman and CEO of UCO NV, Chairman
of Pentahold, Chairman of Smartphoto Group and Chairman
of the Festival Van Vlaanderen. Baron Vlerick is also Vice-
chairman of KBC Group and is a member of the board of
directors of Exmar, Besix Group, Mediahuis, BMT and L.V.D.
(Belgium). Mr Vlerick holds a Degree in Philosophy and
Law from the University of Leuven, and an MBA General
Management degree (PUB) (Ghent, Vlerick School of
Management – 1979). He also holds a master’s degree in
Business Administration from Indiana University, Bloomington
(US – 1980). In 2006, he was voted Manager of the Year
by Trends, a leading business magazine in Belgium. He was
granted the title of Baron in 2008 and became Commander
of the Order of Leopold in 2013.
Dr. Adrienne Graves, Non-Executive, Independent
Director
Dr. Graves is a board member of multiple companies and
organizations including IVERIC bio, Nicox, the American
Society of Cataract and Refractive Surgery, the Glaucoma
Research Foundation, and the Foundation Fighting Blindness.
She was the president and chief executive officer of Santen,
Inc., the US arm of Japan’s largest ophthalmic pharma-
ceutical company, Santen Pharmaceutical Co., Ltd. Before
becoming the president and chief executive officer, she was
the vice president of clinical affairs and senior vice president
of worldwide clinical affairs for Japan, US and Europe at
Santen, Inc. Prior to Santen, Inc., Dr. Graves was the director